Inventor · disambiguated record

Yuelei Shen

Also filed as: SHEN YUELEI

45 granted patents·39 pending applications·32 citations·filing 2015–2024

96Inventor score

Technology areasC07K A01K A61K C12N G01N

Files withBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD59 EUCURE BEIJING BIOPHARMA CO LTD17 BEIJING BIOCYTOGEN CO LTD3 BIOCYTOGEN BOSTON CORP2 BIOCYTOGEN JIANGSU CO LTD2

Top patents by PatentIndex Score

84 records

0191US10918095B2Genetically modified mice expressing humanized CD47BEIJING BIOCYTOGEN CO LTD·Filed 2019·Granted Feb 16, 2021·5 cites·15 claims
0291US10314297B2DNA knock-in systemBIOCYTOGEN BOSTON CORP·Filed 2017·Granted Jun 11, 2019·7 cites·20 claims
0390US10820580B2Immunodeficient non-human animalBEIJING BIOCYTOGEN CO LTD·Filed 2019·Granted Nov 3, 2020·5 cites·7 claims
0489US10934365B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Mar 2, 2021·2 cites·25 claims
0588US11352429B2Anti-PD-1 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Granted Jun 7, 2022·1 cites·26 claims
0688US10973212B2Genetically modified non-human animal with human or chimeric SIRPaBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Apr 13, 2021·4 cites·19 claims
0785US11142582B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Oct 12, 2021·1 cites·14 claims
0883US11439132B2Humanized transgenic animalBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Sep 13, 2022·1 cites·14 claims
0982US11034764B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Jun 15, 2021·1 cites·18 claims
1082US10945420B2Genetically modified non-human animal with human or chimeric CD3eBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Mar 16, 2021·1 cites·18 claims
1182US10912287B2Genetically modified mice expressing humanized PD-1BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted Feb 9, 2021·2 cites·13 claims
1281US2025129164A1Anti-pd-1 antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2024·Application pending·0 cites
1380US10925264B2Genetically modified non-human animal with human or chimeric LAG-3BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Feb 23, 2021·1 cites·12 claims
1480US2025034271A1Anti-cd40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
1580US2025034256A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
1679US2024343806A1Anti-ctla4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
1778US2024352141A1Anti-ox40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
1877US2024092922A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
1976US2024284885A1Genetically modified non-human animals with common light chain immunoglobulin locusBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2024·Application pending·0 cites
2075US12180281B2Anti-PD-1 antibodies and methods of treating cancerBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Granted Dec 31, 2024·0 cites·30 claims
2175US2024373831A1Genetically modified non-human animals with humanized immunoglobulin locusBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2024·Application pending·0 cites
2273US11997994B2Genetically modified non-human animals with common light chain immunoglobulin locusBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Granted Jun 4, 2024·0 cites·18 claims
2373US11730151B2Genetically modified non-human animals with humanized immunoglobulin locusBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Granted Aug 22, 2023·0 cites·19 claims
2472US12134653B2Anti-CD40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Nov 5, 2024·0 cites·16 claims
2572US11723348B2Genetically modified mice expressing humanized CD47BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Aug 15, 2023·0 cites·13 claims
2672US11279948B2Genetically modified non-human animal with human or chimeric OX40BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted Mar 22, 2022·1 cites·11 claims
2771US2025122292A1Anti-egfr/met antibodies and uses thereofDOMA BIOPHARMACEUTICAL SUZHOU CO LTD·Filed 2024·Application pending·0 cites
2870US11071290B2Genetically modified non-human animal with human or chimeric CTLA-4BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Jul 27, 2021·0 cites·13 claims
2970US2022251229A1Anti-tnfrsf9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
3069US11292849B2Anti-TNFRSF9 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Apr 5, 2022·0 cites·33 claims
3169US2024360201A1Modified immunoglobulinsBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2024·Application pending·0 cites
3269US2023043907A1Humanized transgenic animalBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Application pending·0 cites
3368US12342800B2Immunodeficient non-human animalBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Jul 1, 2025·0 cites·21 claims
3468US2025382373A1Anti-egfr/met antibodies and uses thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2023·Application pending·0 cites
3567US12054547B2Anti-CTLA4 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Aug 6, 2024·0 cites·18 claims
3667US11999790B2Anti-OX40 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Granted Jun 4, 2024·0 cites·17 claims
3767US11154041B2Genetically modified non-human animal with human or chimeric genesBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Oct 26, 2021·0 cites·17 claims
3867US2021403570A1Anti-pd-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
3966US12016315B2Genetically modified non-human animal with human or chimeric CD3eBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Granted Jun 25, 2024·0 cites·19 claims
4065US12004495B2Genetically modified non-human animals with humanized immunoglobulin locusBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2020·Granted Jun 11, 2024·0 cites·22 claims
4165US11987615B2Modified immunoglobulinsBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2022·Granted May 21, 2024·0 cites·17 claims
4265US11155625B2Anti-PD-1 antibodies and uses thereofEUCURE BEIJING BIOPHARMA CO LTD·Filed 2020·Granted Oct 26, 2021·0 cites·43 claims
4365US10980222B2Genetically modified non-human animal with human or chimeric CD27BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Apr 20, 2021·0 cites·12 claims
4464US11464876B2Genetically modified mouse comprising a chimeric TIGITBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Oct 11, 2022·0 cites·5 claims
4564US11234420B2Method for constructing PD-1 gene modified humanized animal model and use thereofBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Feb 1, 2022·0 cites·15 claims
4664US2022000086A1Genetically modified non-human animal with human or chimeric genesBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2021·Application pending·0 cites
4763US11240995B2Genetically modified non-human animal with human or chimeric TIM-3BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Feb 8, 2022·0 cites·20 claims
4863US2025185635A1Genetically modified non-human animals with humanized immunoglobulin and mhc lociBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2023·Application pending·0 cites
4962US11096383B2Method of using a genetically modified mouse that expresses a humanized CTLA-4 geneBIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2017·Granted Aug 24, 2021·0 cites·13 claims
5061US11505806B2Genetically modified non-human animal with human or chimeric OX40BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD·Filed 2019·Granted Nov 22, 2022·0 cites·9 claims

Showing the top 50 of 84 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Yuelei Shen files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →